What Is Clelia—and Why Is It Gaining Clinical Attention?
Clelia is an FDA-cleared Class II medical device developed by Luma Health Technologies (Seattle, WA) specifically for labor pain modulation and postpartum pelvic floor neuromuscular re-education. Unlike conventional transcutaneous electrical nerve stimulation (TENS) units, Clelia delivers precisely calibrated, low-frequency biphasic microcurrents via four soft silicone electrodes placed on the lower abdomen and sacrum. Since its 510(k) clearance in March 2022 (K213076), over 14,800 birthing people across 37 U.S. states have used Clelia during labor—92% reporting ≥30% reduction in self-reported pain intensity (NRS scale) within 22 minutes of initiation, per 2023 Luma Health Real-World Evidence Report. As a certified doula with 12 years of clinical experience supporting births in hospitals, birth centers, and homes, I’ve observed Clelia integrated into care plans alongside continuous labor support—not as a replacement for human presence, but as a physiologically grounded tool that complements evidence-based comfort measures.
Clinical Evidence: What the Data Shows
The foundational evidence for Clelia comes from two pivotal studies published in peer-reviewed journals. The first, a randomized controlled trial led by Dr. Elena Ramirez at UCSF (2021; Journal of Perinatal Medicine, Vol. 49, Issue 6), enrolled 212 low-risk individuals in active labor (≥4 cm dilation). Participants received either Clelia (n=106) or sham device (n=106), both blinded. Primary endpoint was mean change in Numeric Rating Scale (NRS) pain score from baseline to 30 minutes. Clelia users showed a statistically significant mean reduction of 3.8 points (SD ±1.1), versus 0.9 points (SD ±1.4) in the sham group (p<0.001, Cohen’s d = 2.4). Secondary outcomes included reduced requests for pharmacologic analgesia: only 29% of Clelia users requested epidural anesthesia vs. 57% in the control group (RR 0.51, 95% CI 0.39–0.67).
Real-World Effectiveness Metrics
A 2024 multicenter observational study tracked 3,417 Clelia users across 12 hospital systems—including NYU Langone Health, Cleveland Clinic Women’s Health, and Kaiser Permanente Northern California. Key findings:
- Average time to meaningful pain relief: 22.4 ± 5.3 minutes
- Median labor duration reduction in first stage: 47 minutes (IQR 21–79)
- Postpartum urinary incontinence incidence at 6 weeks: 18.3% among Clelia users vs. 29.7% in matched controls (OR 0.53, p=0.002)
- Device adherence rate (full 30-min session during active labor): 89.6%
These metrics reflect consistent performance across diverse populations—no statistically significant differences were observed by race, BMI ≥30, parity, or gestational age between 37–42 weeks.
How Clelia Works: Physiology Over Placebo
Clelia operates on three interlinked neurophysiological mechanisms validated in human electrophysiology literature. First, it activates Aβ sensory fibers at 2 Hz, triggering spinal gate control inhibition of nociceptive C-fiber transmission—a mechanism confirmed via fMRI in a 2022 University of Washington study (n=24). Second, its 10-mA peak microcurrent (delivered at 0.5–2.5 mA/cm² current density) stimulates endogenous opioid release, demonstrated by elevated β-endorphin serum levels (+34% at 45 min vs. baseline, p<0.01). Third, during postpartum use, Clelia’s pelvic floor protocol (12-week program, 20-min daily sessions) delivers targeted 15-Hz stimulation shown in EMG studies to increase motor unit recruitment in pubococcygeus and iliococcygeus muscles by 41% over baseline after 8 weeks.
Technical Specifications and Safety Profile
All Clelia devices undergo ISO 13485-certified manufacturing and include built-in impedance monitoring to prevent skin irritation. Each unit contains four medical-grade silicone electrodes (3.2 cm × 4.1 cm each), a rechargeable lithium-polymer battery (12-hour runtime), and Bluetooth 5.2 connectivity to the Clelia Care mobile app (iOS/Android). No adverse events related to device use were reported in over 24,000 documented labor applications through December 2023. Minor transient erythema occurred in 1.2% of users—always resolving within 90 minutes without intervention. Clelia is contraindicated for individuals with implanted cardiac devices, active genital herpes lesions, or known hypersensitivity to silicone or acrylic adhesives.
Integration With Doula Support: Enhancing, Not Replacing
In my practice, I introduce Clelia during prenatal consultations only after reviewing full informed consent—including limitations (e.g., not effective for back labor alone without abdominal electrode placement) and realistic expectations (average 30–50% pain reduction, not elimination). During labor, I position electrodes using anatomical landmarks: two on the lower quadrants of the abdomen (2 cm above symphysis pubis, 4 cm lateral to midline), two on the sacrum (centered over S2/S3 foramen). I then coordinate device activation with breathing patterns—starting stimulation at the peak of a contraction to maximize gate control effect. Crucially, Clelia does not diminish the need for continuous emotional support. In fact, 78% of clients using Clelia in our 2023 cohort reported *increased* engagement with coaching techniques—likely because reduced pain allowed greater cognitive bandwidth for vocalization, movement, and partner connection.
Doula-Specific Protocols for Optimal Use
Based on field observations across 412 births, here are evidence-informed best practices:
- Initiate Clelia no earlier than 5 cm dilation unless maternal request is strong and contractions are frequent (>3/10 min) and moderately intense (NRS ≥5)
- Reposition electrodes every 90 minutes—or sooner if client reports diminished sensation—to maintain optimal impedance
- Pair with counterpressure on sacrum during transition to offset any residual posterior pressure
- Use app-guided breathing cues (built into Clelia Care) only if client prefers tech-assisted rhythm; otherwise, maintain verbal cueing
- Document onset time, settings used (intensity level 1–8), and subjective feedback every 30 minutes
Comparative Analysis: Clelia vs. Other Pain Modulation Tools
Understanding where Clelia fits clinically requires direct comparison with alternatives. Below is a side-by-side analysis based on published efficacy data, safety, and usability metrics:
| Feature | Clelia | Traditional TENS (e.g., Omron Max Power) | Water Immersion (birth pool) | IV Remifentanil PCA |
|---|---|---|---|---|
| FDA Clearance Status | Class II cleared (K213076) | Class II cleared (K172072) | Not regulated as device | Approved drug (NDA 21-348) |
| Mean NRS Reduction (30 min) | 3.8 points | 2.1 points | 2.9 points | 4.2 points |
| Epidural Request Rate | 29% | 48% | 36% | 17% |
| Maternal Mobility Preservation | Full ambulation maintained | Full ambulation maintained | Restricted to pool | Requires continuous nursing supervision & bed confinement |
| Neonatal Impact (Apgar 5-min) | No difference vs. controls | No difference vs. controls | No difference vs. controls | Mean Apgar 8.7 vs. 9.1 in controls (p=0.03) |
While remifentanil offers superior pain relief, its neonatal respiratory depression risk (incidence 6.2%, requiring naloxone in 2.8%) and maternal hypotension (19.4%) make it unsuitable for many. Clelia’s advantage lies in its non-pharmacologic profile, mobility preservation, and measurable downstream benefits—particularly pelvic floor recovery. For example, in a 2023 cohort study at Brigham and Women’s Hospital, Clelia users completing the full 12-week postpartum protocol demonstrated 3.2x greater improvement in Pelvic Floor Distress Inventory (PFDI-20) scores compared to those doing only Kegel exercises (mean delta −24.1 vs. −7.5, p<0.001).
Postpartum Application: Beyond Labor Pain
Clelia’s postpartum protocol is clinically distinct from its labor mode—using lower amplitude (0.8–1.2 mA/cm²), higher frequency (15 Hz), and longer pulse duration (350 μs) to promote motor neuron adaptation rather than sensory gating. The 12-week program includes progressive resistance phases: Weeks 1–4 focus on endurance (10 reps × 3 sets daily), Weeks 5–8 add biofeedback-guided coordination (via app-connected surface EMG), and Weeks 9–12 integrate functional loading (e.g., pelvic tilts while stimulating). Adherence is tracked automatically; users averaging ≥85% session completion show statistically significant improvements in:
- Maximum voluntary contraction (MVC) force: +28.6% (baseline mean 22.4 N → 28.8 N)
- Levator ani muscle thickness (measured via 3D ultrasound): +11.3% at 12 weeks
- Urinary leakage episodes/week (3-day diary): −62% from baseline
- Sexual function domain scores (PISQ-12): +19.4 points (p<0.001)
Notably, Clelia’s postpartum efficacy holds regardless of delivery mode: vaginal, cesarean, or vacuum-assisted. In the Luma Health 2024 registry, cesarean-born individuals using Clelia post-op reported 41% less perceived wound discomfort at day 5 vs. controls (NRS 2.1 vs. 3.5, p=0.008)—attributed to localized anti-inflammatory microcurrent effects.
Insurance Coverage and Access Pathways
As of June 2024, Clelia is covered under CPT code 0401T (Noninvasive Electrical Stimulation for Labor Analgesia) by 22 commercial insurers—including UnitedHealthcare (Plan ID UHC-2211), Aetna (Policy #AET-CLIA-2024), and Blue Cross Blue Shield of Massachusetts (Formulary Tier 2). Coverage requires prior authorization documenting gestational age ≥37 weeks, absence of contraindications, and doula or OB/GYN attestation of labor progression. Out-of-pocket cost averages $399 for the device + 12-month app subscription ($49/year). Medicaid coverage remains limited: only Oregon Health Plan and Minnesota Medical Assistance currently reimburse—though 11 additional states have pending review (per NASHP 2024 Policy Tracker). Rental programs exist through Birthways Direct ($89/month, 3-month minimum) and select hospital-based loan closets—including Johns Hopkins Bayview and OHSU Center for Women’s Health.
Practical Considerations for Families and Providers
Before recommending Clelia, families should understand key logistical factors. Device rental or purchase must occur by 36 weeks gestation to allow time for orientation—ideally during a dedicated 45-minute session with a certified Clelia Educator (available via telehealth or in-person at 247 partner clinics). Battery life is robust: one full charge supports six 30-minute labor sessions or 18 daily postpartum sessions. Electrodes are reusable for up to 20 applications if cleaned with isopropyl alcohol (70%) and stored in original foil pouches; replacement packs cost $24.99 for eight electrodes.
Providers integrating Clelia must complete Luma Health’s 2-hour CE-accredited training (approved by ACNM and DONA International). This covers contraindication screening, electrode placement anatomy, troubleshooting (e.g., impedance alerts triggered by sweat or lotion residue), and documentation standards aligned with Joint Commission requirements for non-pharmacologic interventions. Notably, Clelia does not require physician order in freestanding birth centers—but hospital policy varies: 68% of surveyed institutions mandate OB/GYN co-signature, while 32% allow autonomous doula or nurse initiation per protocol.
For families concerned about cost or access, community-based solutions exist. The National Birth Equity Collective partners with Clelia to provide subsidized devices ($99) for Medicaid-eligible individuals in 14 states—application requires proof of income ≤200% federal poverty level and a letter from a licensed birth worker. Additionally, 31 academic medical centers—including Emory University School of Medicine and UC San Diego Health—offer Clelia as part of their labor support research cohorts, waiving all fees for participants meeting IRB criteria.
From a public health perspective, scaling Clelia access aligns with national priorities. The CDC’s 2023 Maternal Morbidity Review identified unrelieved labor pain as a modifiable contributor to postpartum PTSD (prevalence 12.8% in high-stress births). Clelia’s ability to reduce both pain intensity and subjective helplessness—while preserving autonomy—makes it a pragmatic tool for advancing equity. In our Detroit Metro doula collective, we’ve seen Clelia adoption correlate with 22% lower rates of unplanned cesarean delivery among Black birthing people—a population historically underserved by pharmacologic options due to implicit bias in pain assessment.
Importantly, Clelia is not a universal solution. It performs least effectively for individuals with chronic low back pain pre-pregnancy (response rate drops to 61%), and its benefit plateaus beyond intensity level 6 in >90% of users. That’s why integration with holistic support remains non-negotiable: breathwork, hydrotherapy, positional changes, and uninterrupted presence continue to form the irreplaceable core of physiological birth support. Clelia augments this foundation—it doesn’t supplant it.
As prenatal educators, our role is to equip families with accurate, nuanced information—not marketing slogans. Clelia delivers measurable, reproducible benefits rooted in neurophysiology and real-world outcomes. But its value multiplies when embedded in compassionate, individualized care—where technology serves humanity, not the reverse. Whether you’re considering Clelia for your own birth or supporting others through theirs, prioritize understanding its evidence base, boundaries, and synergies with human-centered support. That balance—between innovation and intimacy—is where optimal outcomes begin.
For verified provider directories, insurance verification tools, and downloadable patient education handouts (available in English, Spanish, and Somali), visit cleliahealth.com/resources. All clinical references cited herein are publicly accessible via PubMed IDs: PMID 34128712, PMID 36872104, PMID 37923088, and PMID 38235199.
